{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:39:52Z","timestamp":1789468792632,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00393-025-01687-z","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:30:17Z","timestamp":1762428617000},"page":"83-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Management des systemischen Lupus erythematodes\u00a0\u2013 inklusive sekund\u00e4rem Antiphospholipidsyndrom, Kinderwunsch und Schwangerschaft","Management of systemic lupus erythematosus\u2014Including secondary antiphospholipid syndrome, fertility and pregnancy"],"prefix":"10.1007","volume":"84","author":[{"given":"J.","family":"Mucke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-J.","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Berlit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"B\u00f6ltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.-C.","family":"Burchardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fischer-Betz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. F.","family":"Hoyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-M.","family":"Lorenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Meder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Miesbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Reuss-Borst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Schanze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schwarting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Seeliger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Specker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tenbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Weinmann-Menke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Bertsias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"issue":"6","key":"1687_CR1","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/annrheumdis-2019-215089","volume":"78","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Alunno\u00a0A et\u00a0al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736\u2013745 (https:\/\/ard.bmj.com\/content\/annrheumdis\/78\/6\/736\/DC2\/embed\/inline-supplementary-material-2.docx?download=true)","journal-title":"Ann Rheum Dis"},{"key":"1687_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224762","author":"A Fanouriakis","year":"2023","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Andersen\u00a0J et\u00a0al (2023) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1687_CR3","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2020","unstructured":"Fanouriakis\u00a0A, Kostopoulou\u00a0M, Cheema\u00a0K et\u00a0al (2020) 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79(6):713\u2013723. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216924","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"1687_CR4","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","volume":"78","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou\u00a0MG, Andreoli\u00a0L, Limper\u00a0M et\u00a0al (2019) EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 78(10):1296\u20131304","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1687_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","volume":"76","author":"L Andreoli","year":"2017","unstructured":"Andreoli\u00a0L, Bertsias\u00a0GK, Agmon-Levin\u00a0N et\u00a0al (2017) EULAR recommendations for women\u2019s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome. Ann Rheum Dis 76(3):476\u2013485. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209770","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1687_CR6","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","volume":"78","author":"M Aringer","year":"2019","unstructured":"Aringer\u00a0M, Costenbader\u00a0K, Daikh\u00a0D et\u00a0al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis 78(9):1151\u20131159","journal-title":"Ann Rheum Dis"},{"key":"1687_CR7","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Bertsias G, Doria A et\u00a0al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8(1)","DOI":"10.1136\/annrheumdis-2021-eular.1192"},{"key":"1687_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220920","author":"RA Furie","year":"2021","unstructured":"Furie\u00a0RA, Aroca\u00a0G, Cascino\u00a0MD et\u00a0al (2021) B\u2011cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a\u00a0randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1687_CR9","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1093\/rheumatology\/keac150","volume":"61","author":"J Arnold","year":"2022","unstructured":"Arnold\u00a0J, Dass\u00a0S, Twigg\u00a0S et\u00a0al (2022) Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab. Rheumatology (Oxford) 61(12):4905\u20134909","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"1687_CR10","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/annrheumdis-2021-221756","volume":"81","author":"P Kvacskay","year":"2022","unstructured":"Kvacskay\u00a0P, Merkt\u00a0W, G\u00fcnther\u00a0J et\u00a0al (2022) Obinutuzumab in connective tissue diseases after former rituximab-non-response: a\u00a0case series. Ann Rheum Dis 81(5):744\u2013746. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221756","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1687_CR11","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos\u00a0D, Kr\u00f6nke\u00a0G, V\u00f6lkl\u00a0S et\u00a0al (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N\u00a0Engl J Med 385(6):567\u2013569","journal-title":"N Engl J Med"},{"key":"1687_CR12","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und medizinische Onkologie (DGHO) Leitlinie Immunthrombozytopenie 2024. https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/immunthrombozytopenie-itp\/@@guideline\/html\/index.html. Zugegriffen: 7. Nov. 2024"},{"issue":"1","key":"1687_CR13","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1365-2702.2008.01010.x","volume":"1","author":"K Miljeteig","year":"2009","unstructured":"Miljeteig\u00a0K, Graue\u00a0M (2009) Evaluation of a\u00a0multidisciplinary patient education program for people with systemic lupus erythematosus. J\u00a0Nurs Healthc 1(1):87\u201395","journal-title":"J Nurs Healthc"},{"issue":"1","key":"1687_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s42358-019-0074-8","volume":"59","author":"TC Da Hora","year":"2019","unstructured":"Da Hora\u00a0TC, Lima\u00a0K, Maciel\u00a0RRBT (2019) The effect of therapies on the quality of life of patients with systemic lupus erythematosus: a\u00a0meta-analysis of randomized trials. Adv Rheumatol 59(1):34. https:\/\/doi.org\/10.1186\/s42358-019-0074-8","journal-title":"Adv Rheumatol"},{"issue":"3","key":"1687_CR15","first-page":"298","volume":"1","author":"H Liang","year":"2014","unstructured":"Liang\u00a0H, Tian\u00a0X, Cao\u00a0L\u2011Y et\u00a0al (2014) Effect of psychological intervention on health-related quality of life in people with systemic lupus erythematosus: A\u00a0systematic review. Int J Nurs Sci 1(3):298\u2013305","journal-title":"Int J Nurs Sci"},{"issue":"2","key":"1687_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.semarthrit.2017.04.003","volume":"47","author":"T O\u2019Dwyer","year":"2017","unstructured":"O\u2019Dwyer\u00a0T, Durcan\u00a0L, Wilson\u00a0F (2017) Exercise and physical activity in systemic lupus erythematosus: a\u00a0systematic review with meta-analyses. Semin Arthritis Rheum 47(2):204\u2013215. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.04.003","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1687_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1111\/wvn.12221","volume":"14","author":"M-L Wu","year":"2017","unstructured":"Wu\u00a0M\u2011L, Yu\u00a0K\u2011H, Tsai\u00a0J\u2011C (2017) The effectiveness of exercise in adults with systemic lupus erythematosus: a\u00a0systematic review and meta-analysis to guide evidence-based practice. Worldviews Evid Based Nurs 14(4):306\u2013315. https:\/\/doi.org\/10.1111\/wvn.12221","journal-title":"Worldviews Evid Based Nurs"},{"issue":"3","key":"1687_CR18","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/annrheumdis-2019-216303","volume":"79","author":"A Mathian","year":"2020","unstructured":"Mathian\u00a0A, Pha\u00a0M, Haroche\u00a0J et\u00a0al (2020) Withdrawal of low-dose prednisone in SLE patients with a\u00a0clinically quiescent disease for more than 1\u00a0year: a\u00a0randomised clinical trial. Ann Rheum Dis 79(3):339\u2013346. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216303","journal-title":"Ann Rheum Dis"},{"issue":"34","key":"1687_CR19","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM et\u00a0al (2021) 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart\u00a0J 42(34):3227\u20133337","journal-title":"Eur Heart J"},{"key":"1687_CR20","doi-asserted-by":"publisher","first-page":"107466","DOI":"10.1016\/j.intimp.2021.107466","volume":"94","author":"X Lu","year":"2021","unstructured":"Lu\u00a0X, Wang\u00a0Y, Zhang\u00a0J et\u00a0al (2021) Patients with systemic lupus erythematosus face a\u00a0high risk of cardiovascular disease: a\u00a0systematic review and meta-analysis. Int Immunopharmacol 94:107466. https:\/\/doi.org\/10.1016\/j.intimp.2021.107466","journal-title":"Int Immunopharmacol"},{"issue":"38","key":"1687_CR21","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy\u00a0JW, McCarthy\u00a0CP, Bruno\u00a0RM et\u00a0al (2024) 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart\u00a0J 45(38):3912\u20134018","journal-title":"Eur Heart J"},{"issue":"1","key":"1687_CR22","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.autrev.2018.08.002","volume":"18","author":"M Adawi","year":"2019","unstructured":"Adawi\u00a0M, Bragazzi\u00a0NL, McGonagle\u00a0D et\u00a0al (2019) Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: an evidence-informed and PRISMA compliant systematic review and meta-analysis. Autoimmun Rev 18(1):73\u201392. https:\/\/doi.org\/10.1016\/j.autrev.2018.08.002","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1687_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/14760584.2021.1889375","volume":"20","author":"V Infante","year":"2021","unstructured":"Infante\u00a0V, Miyaji\u00a0KT, Soarez\u00a0PC et\u00a0al (2021) Systematic review and meta-analysis of HPV vaccination in women with systemic lupus erythematosus (SLE). Expert Rev Vaccines 20(3):309\u2013318. https:\/\/doi.org\/10.1080\/14760584.2021.1889375","journal-title":"Expert Rev Vaccines"},{"issue":"5","key":"1687_CR24","first-page":"882","volume":"29","author":"MB Aytac","year":"2011","unstructured":"Aytac\u00a0MB, Kasapcopur\u00a0O, Aslan\u00a0M et\u00a0al (2011) Hepatitis\u00a0B vaccination in juvenile systemic lupus erythematosus. Clin Exp Rheumatol 29(5):882\u2013886","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"1687_CR25","first-page":"791","volume":"30","author":"CMPL Barbosa","year":"2012","unstructured":"Barbosa\u00a0CMPL, Terreri\u00a0MTRA, Ros\u00e1rio\u00a0PO et\u00a0al (2012) Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin Exp Rheumatol 30(5):791\u2013798","journal-title":"Clin Exp Rheumatol"},{"issue":"19","key":"1687_CR26","doi-asserted-by":"publisher","first-page":"e3637","DOI":"10.1097\/MD.0000000000003637","volume":"95","author":"Y Huang","year":"2016","unstructured":"Huang\u00a0Y, Wang\u00a0H, Wan\u00a0L et\u00a0al (2016) Is systemic lupus erythematosus associated with a\u00a0declined immunogenicity and poor safety of influenza vaccination? A\u00a0systematic review and meta-analysis. Medicine (Baltimore) 95(19):e3637","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"1687_CR27","doi-asserted-by":"publisher","first-page":"e0147856","DOI":"10.1371\/journal.pone.0147856","volume":"11","author":"Z Liao","year":"2016","unstructured":"Liao\u00a0Z, Tang\u00a0H, Xu\u00a0X et\u00a0al (2016) Immunogenicity and safety of influenza vaccination in systemic lupus erythematosus patients compared with healthy controls: a\u00a0meta-analysis. PLoS ONE 11(2):e147856. https:\/\/doi.org\/10.1371\/journal.pone.0147856","journal-title":"PLoS ONE"},{"issue":"12","key":"1687_CR28","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1136\/annrheumdis-2019-215925","volume":"78","author":"CC Mok","year":"2019","unstructured":"Mok\u00a0CC, Chan\u00a0KH, Ho\u00a0LY et\u00a0al (2019) Safety and immune response of a\u00a0live-attenuated herpes zoster vaccine in patients with systemic lupus erythematosus: a\u00a0randomised placebo-controlled trial. Ann Rheum Dis 78(12):1663\u20131668. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215925","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"1687_CR29","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/kew211","volume":"55","author":"M Pug\u00e8s","year":"2016","unstructured":"Pug\u00e8s\u00a0M, Biscay\u00a0P, Barnetche\u00a0T et\u00a0al (2016) Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a\u00a0systematic literature review and meta-analysis. Rheumatology (Oxford) 55(9):1664\u20131672. https:\/\/doi.org\/10.1093\/rheumatology\/kew211","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"1687_CR30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.amjmed.2021.08.038","volume":"135","author":"JJL Sim","year":"2022","unstructured":"Sim\u00a0JJL, Lim\u00a0CC (2022) Influenza vaccination in systemic lupus erythematosus: efficacy, effectiveness, safety, utilization, and barriers. Am J Med 135(3):286\u2013296.e9. https:\/\/doi.org\/10.1016\/j.amjmed.2021.08.038","journal-title":"Am J Med"},{"key":"1687_CR31","volume-title":"Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut","author":"RKI","year":"2024","unstructured":"RKI (2024) Empfehlungen der St\u00e4ndigen Impfkommission (STIKO) beim Robert Koch-Institut"},{"issue":"6","key":"1687_CR32","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1136\/annrheumdis-2021-221733","volume":"81","author":"GC Drosos","year":"2022","unstructured":"Drosos\u00a0GC, Vedder\u00a0D, Houben\u00a0E et\u00a0al (2022) EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 81(6):768\u2013779. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221733","journal-title":"Ann Rheum Dis"},{"key":"1687_CR33","doi-asserted-by":"crossref","unstructured":"Wang H, Li T, Sun F et\u00a0al (2022) Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a\u00a0phase\u00a0I\/II trial. RMD Open 8(2)","DOI":"10.1136\/rmdopen-2022-002686"},{"issue":"1S","key":"1687_CR34","first-page":"S1","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) (2024) KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int 105(1S):S1\u2013S69 (https:\/\/kdigo.org\/wp-content\/uploads\/2024\/02\/KDIGO-2024-Lupus-Nephritis-Guideline-Data-Supplement.pdf)","journal-title":"Kidney Int"},{"key":"1687_CR35","doi-asserted-by":"crossref","unstructured":"Kostopoulou M, Fanouriakis A, Cheema K et\u00a0al (2020) Management of lupus nephritis: a\u00a0systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations. RMD Open 6(2)","DOI":"10.1136\/rmdopen-2020-001263"},{"issue":"7","key":"1687_CR36","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","volume":"56","author":"V Reddy","year":"2017","unstructured":"Reddy\u00a0V, Klein\u00a0C, Isenberg\u00a0DA et\u00a0al (2017) Obinutuzumab induces superior B\u2011cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples. Rheumatology (Oxford) 56(7):1227\u20131237","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"1687_CR37","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1136\/ard-2023-224609","volume":"82","author":"M Barbhaiya","year":"2023","unstructured":"Barbhaiya\u00a0M, Zuily\u00a0S, Naden\u00a0R et\u00a0al (2023) 2023 ACR\/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 82(10):1258\u20131270. https:\/\/doi.org\/10.1136\/ard-2023-224609","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"1687_CR38","doi-asserted-by":"publisher","first-page":"e000924","DOI":"10.1136\/rmdopen-2019-000924","volume":"5","author":"MG Tektonidou","year":"2019","unstructured":"Tektonidou\u00a0MG, Andreoli\u00a0L, Limper\u00a0M et\u00a0al (2019) Management of thrombotic and obstetric antiphospholipid syndrome: a\u00a0systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open 5(1):e924. https:\/\/doi.org\/10.1136\/rmdopen-2019-000924","journal-title":"RMD Open"},{"issue":"1","key":"1687_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","volume":"81","author":"CD Khairani","year":"2023","unstructured":"Khairani\u00a0CD, Bejjani\u00a0A, Piazza\u00a0G et\u00a0al (2023) Direct oral anticoagulants vs vitamin\u00a0K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials. J\u00a0Am Coll Cardiol 81(1):16\u201330. https:\/\/doi.org\/10.1016\/j.jacc.2022.10.008","journal-title":"J Am Coll Cardiol"},{"key":"1687_CR40","doi-asserted-by":"crossref","unstructured":"Koval N, Alves M, Pl\u00e1cido R et\u00a0al (2021) Direct oral anticoagulants versus vitamin\u00a0K antagonists in patients with antiphospholipid syndrome: systematic review and meta-analysis. RMD Open 7(2)","DOI":"10.1136\/rmdopen-2021-001678"},{"key":"1687_CR41","unstructured":"Deutsche Gesellschaft f\u00fcr Angiologie (2023) S2k-Leitlinie Diagnostik und Therapie der Venenthrombose und Lungenembolie. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/065-002. Zugegriffen: 14. Nov. 2024"},{"key":"1687_CR42","unstructured":"AWMF (2015) S3-Leitlinie Prophylaxe der ven\u00f6sen Thromboembolie (VTE). https:\/\/register.awmf.org\/de\/leitlinien\/detail\/065-002. Zugegriffen: 14. Nov. 2024"},{"issue":"12","key":"1687_CR43","doi-asserted-by":"publisher","first-page":"5610","DOI":"10.1093\/rheumatology\/keab155","volume":"60","author":"C Tani","year":"2021","unstructured":"Tani\u00a0C, Zucchi\u00a0D, Haase\u00a0I et\u00a0al (2021) Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A\u00a0multicentre study. Rheumatology (Oxford) 60(12):5610\u20135619","journal-title":"Rheumatology (Oxford)"},{"key":"1687_CR44","doi-asserted-by":"crossref","unstructured":"Wind M, Hendriks M, van Brussel BTJ et\u00a0al (2021) Effectiveness of a\u00a0multidisciplinary clinical pathway for women with systemic lupus erythematosus and\/or antiphospholipid syndrome. Lupus Sci Med 8(1)","DOI":"10.1136\/lupus-2020-000472"},{"issue":"5","key":"1687_CR45","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/0961203321989803","volume":"30","author":"A Rajendran","year":"2021","unstructured":"Rajendran\u00a0A, Eudy\u00a0AM, Balevic\u00a0SJ et\u00a0al (2021) The importance of pregnancy planning in lupus pregnancies. Lupus 30(5):741\u2013751. https:\/\/doi.org\/10.1177\/0961203321989803","journal-title":"Lupus"},{"issue":"4","key":"1687_CR46","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","volume":"62","author":"MD Russell","year":"2023","unstructured":"Russell\u00a0MD, Dey\u00a0M, Flint\u00a0J et\u00a0al (2023) British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 62(4):e48\u2013e88","journal-title":"Rheumatology (Oxford)"},{"issue":"13","key":"1687_CR47","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1177\/0961203315591027","volume":"24","author":"M Leroux","year":"2015","unstructured":"Leroux\u00a0M, Desveaux\u00a0C, Parcevaux\u00a0M et\u00a0al (2015) Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a\u00a0descriptive cohort study. Lupus 24(13):1384\u20131391. https:\/\/doi.org\/10.1177\/0961203315591027","journal-title":"Lupus"},{"key":"1687_CR48","doi-asserted-by":"crossref","unstructured":"Ling Liu E, Liu Z, Xiu Zhou Y (2018) Feasibility of hydroxychloroquine adjuvant therapy in pregnant women with systemic lupus erythematosus. Biomed Res 29(5)","DOI":"10.4066\/biomedicalresearch.29-17-3539"},{"issue":"7","key":"1687_CR49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik\u00a0DL, Wright\u00a0D, Poon\u00a0LC et\u00a0al (2017) Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N\u00a0Engl J Med 377(7):613\u2013622. https:\/\/doi.org\/10.1056\/NEJMoa1704559","journal-title":"N Engl J Med"},{"issue":"5","key":"1687_CR50","doi-asserted-by":"publisher","first-page":"CD012852","DOI":"10.1002\/14651858.CD012852.pub2","volume":"5","author":"EN Hamuly\u00e1k","year":"2020","unstructured":"Hamuly\u00e1k\u00a0EN, Scheres\u00a0LJ, Marijnen\u00a0MC et\u00a0al (2020) Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev 5(5):CD12852. https:\/\/doi.org\/10.1002\/14651858.CD012852.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1687_CR51","unstructured":"CEBM Levels of Evidence Working Group The Oxford levels of evidence 2. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/ocebm-levels-of-evidence. Zugegriffen: 5. Nov. 2024"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01687-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01687-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01687-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T22:01:43Z","timestamp":1764885703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01687-z"}},"subtitle":["S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie e. V. und Deutsche Gesellschaft f\u00fcr Neurologie e. V. (DGN), Deutsche Gesellschaft f\u00fcr Innere Medizin e. V. (DGIM), Deutsche Gesellschaft f\u00fcr Kardiologie\u00a0\u2013 Herz- und Kreislaufforschung e. V. (DGK), Gesellschaft f\u00fcr Thrombose und H\u00e4mostaseforschung e. V. (GTH), Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Medizinische Onkologie e. V. (DGHO), Deutsche Gesellschaft f\u00fcr Kinder- und Jugendmedizin e. V. (DGKJ), Gesellschaft f\u00fcr Kinder- und Jugendrheumatologie e. V. (GKJR), Deutsche Gesellschaft f\u00fcr Nephrologie e. V. (DGfN), Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin e. V. (DGP), Deutsche Rheuma-Liga Bundesverband e. V., Lupus Erythematodes Selbsthilfegemeinschaft e. V., Deutsche Dermatologische Gesellschaft e. V. (DDG). Version:\u00a01.2","S3 guidelines of the German Society for Rheumatology and Clinical Immunology and the German Society for Neurology (DGN), German Society for Internal Medicine (DGIM), German Cardiac Society (DGK), Society for Thrombosis and Hemostasis Research (GTH), German Society for Hematology and Medical Oncology (DGHO), German Society for Pediatric and Adolescent Medicine (DGKJ), Society for Pediatric and Adolescent Rheumatology (GKJR), German Society for Nephrology (DGfN), German Society for Pneumology and Ventilation Medicine (DGP), German Rheumatism League National Association, Lupus Erythematosus Self-help Community, German Dermatological Society (DDG). Version:\u00a01.2"],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":51,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1687"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01687-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"7 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die Leitlinie wurde durch die federf\u00fchrende Gesellschaft Deutschen Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie e. V. finanziert. Ein finanzieller Einfluss externer Interessentr\u00e4ger bestand nicht. Die Angaben zu den Interessen wurden mithilfe des Portals der AWMF zu Interessenkonflikten und mithilfe des AWMF-Formblatts erhoben und auf einen thematischen Bezug zur Leitlinie bewertet. Potenzielle Interessenkonflikte und entsprechende Einschr\u00e4nkungen in der Erarbeitung der Leitlinie oder den Konsensuskonferenzen aller beteiligter Autorinnen und Autoren sind im AWMF-Portal unter dem Link\n                      \n                      hinterlegt und im Detail ausgef\u00fchrt.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}